Midi Health Becomes The First 'Menopause Unicorn'

Key Concepts

• Midi Health: A women’s health company focused on perimenopause and menopause, expanding into broader preventative and primary care.
• Unicorn Status: Achieving a valuation of $1 billion or more, signifying significant growth and investor confidence.
• Women’s Health Economic Opportunity: The growing recognition of women’s health as a substantial market with unmet needs and potential for innovation.
• Virtual Care: Delivering healthcare services remotely through technology, offering convenience and accessibility.
• Research Institute: Midi Health’s initiative to conduct health research leveraging its extensive patient data to improve care and understand cost savings.
• Metabolic, Musculoskeletal & Long-Term Wellness: New care lines being launched by Midi Health to address a wider range of women’s health needs.

Midi Health: From Next Billion-Dollar Startup to Menopause Unicorn

Introduction

Forbes Women recently featured Midi Health, recognizing it as a “next billion-dollar startup” in 2024. This discussion with founder and CEO Joanna Strober details the company’s journey to achieving a $1 billion+ valuation (“unicorn” status) and outlines its future growth strategy. The conversation highlights the evolving landscape of women’s health investment and the increasing demand for accessible, comprehensive care.

Achieving Unicorn Status & Funding Landscape

Midi Health successfully raised a $100 million funding round led by Goodwater Capital, with participation from Foresight, Serena Ventures, and existing investors. This funding wasn’t driven by a prolonged fundraising period, but rather by the company’s rapid growth and the need for capital to sustain it. Strober emphasized that the fundraising process was “opportunistic,” fueled by a shift in investor perception regarding the economic potential of women’s health. Previously, securing funding was “difficult,” but now investors recognize the significant market opportunity as women actively seek better healthcare solutions and are willing to spend on them. She noted they could have potentially raised even more capital.

Growth & Patient Acquisition

Midi Health has experienced substantial growth, increasing patient treatment from approximately 12,000 women per week in Spring 2024 to over 25,000 patients weekly currently. This expansion spans all 50 US states, with insurance coverage available nationwide. The company is actively hiring and training clinicians to meet the increasing demand, with wait times exceeding a month in some states. This rapid growth is attributed to a broadening scope of care beyond initial focus on menopause symptoms.

Expanding Scope of Care: Beyond Menopause

Initially focused on perimenopause and menopause, Midi Health has evolved into a more comprehensive women’s health provider. Patients often present with symptoms like hot flashes, night sweats, anxiety, and joint pain, but through blood tests and screenings, the company identifies and addresses broader health concerns such as pre-diabetes, cancer (facilitating connections to specialized care), and other preventative health needs. This expansion is driven by patient demand and a recognition of the broader “women’s care gap.” The company is now serving women across a wider age range, from 20 to 80 years old. New care lines addressing metabolic health, weight management, musculoskeletal health, and long-term wellness are planned for launch. Strober clarified that menopause care is holistic women’s health, not separate from it.

Addressing the Primary Care Gap & Time Savings

Midi Health is increasingly functioning as a primary care provider for many patients, filling a significant gap in access to healthcare. The company’s virtual care model offers substantial time savings compared to traditional in-person visits, which Strober estimates take an average of 3.5 hours, while Midi Health visits are typically 30 minutes online.

Economic Impact & Research Institute

Untreated menopause symptoms are estimated to cost $25 billion annually in medical expenses and lost work productivity. Midi Health is actively demonstrating cost savings to investors by potentially reducing the need for specialist care, unnecessary procedures, and overuse of medications like SSRIs (anti-depressants). To further quantify these benefits, Midi Health is launching a research institute. This institute will leverage data from its 300,000+ patient base to identify optimal treatment strategies, personalize care based on genetics and health history, and demonstrate the economic value of proactive women’s health management. The institute’s development was partially influenced by recent reductions in federal health research funding, highlighting the need for independent data collection and analysis.

Maintaining Quality & Future Growth

As Midi Health scales, maintaining the quality of care remains a top priority. The company is investing in both technological solutions, particularly AI, to enhance training and quality monitoring, and in traditional training programs for its clinicians. The appointment of Jason Wheeler, former executive at Tesla and Google, as Chief Financial Officer signals a focus on building an efficient and scalable organization. While an IPO is not currently being discussed, the company’s rapid growth suggests it remains a possibility.

Inflection Point & Scaling Infrastructure

Strober identified an inflection point in growth when the company reached approximately 1,000 visits per week. As they successfully scaled to 2,000 and then 5,000 visits, they built the infrastructure necessary to support continued expansion. She now feels more confident in the company’s ability to scale efficiently due to these established systems.

Core Mission & Patient Base

Midi Health’s primary focus remains on expanding access to high-quality care for more women. The company serves a diverse patient base, including both high-profile executives and factory workers, demonstrating its commitment to equitable healthcare access across socioeconomic backgrounds and geographic locations.

Notable Quote:

“Menopause just means you haven’t had your period for a year. Taking care of women in perimenopause and in menopause is holistic care.” – Joanna Strober

Technical Terms:

• Unicorn: A privately held startup company valued at over $1 billion.
• SSRIs (Selective Serotonin Reuptake Inhibitors): A class of antidepressants commonly prescribed for anxiety and depression.
• PCOS (Polycystic Ovary Syndrome): A hormonal disorder common among women of reproductive age.
• Cross-Sectional Data: Data collected at a single point in time, providing a snapshot of a population.

Conclusion

Midi Health’s journey from a promising startup to a “menopausal unicorn” exemplifies the growing recognition of women’s health as a significant economic opportunity. The company’s rapid growth, expanding scope of care, and commitment to research position it as a key player in addressing the unmet needs of women throughout their lives. By leveraging technology, prioritizing quality, and focusing on patient access, Midi Health aims to fill the existing care gaps and improve the health and well-being of millions of women.